Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.

Matthew R Watts Peter C Taylor Vitali Sintchenko Clair M Whelan Robert H Farnsworth Philip Jones Peter Jelfs David Carr Hazel Goldberg

Clin Infect Dis

Centre for Infectious Diseases and Microbiology Laboratory Services, Level 3, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia.

Published: January 2011

We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For these circumstances, we propose some modifications to existing treatment guidelines for BCG infection.

Download full-text PDF	Source
http://dx.doi.org/10.1093/cid/ciq002	DOI Listing

Publication Analysis

Top Keywords

isoniazid resistance

mycobacterium bovis

bovis bacillus

bacillus calmette-guérin

bladder cancer

editor's choice

choice implications

implications isoniazid

resistance mycobacterium

calmette-guérin immunotherapy

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!